Skip to content
Bored Studies
RecruitingPhase 3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

argenx · NCT06920004

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
218
US sites recruiting
16
Study start
August 22, 2025
Record last updated
October 16, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).

More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Being studied: empasiprubart; IVIg; empasiprubart-placebo; IVIg-placebo

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
  • Has responded to IVIg in the past 5 years
  • Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg
  • Has residual disability and active disease

Exclusion Criteria

  • Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes
  • Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Use of other long-acting immunomodulatory treatment

Recruiting US locations

  • University of Alabama

    Birmingham, AL 35233

    Site contact: Eroboghene Ubogu, MD · 857-350-4834 · ubogu@uab.edu

  • Samir Macwan, M.D., Inc.

    Rancho Mirage, CA 922701

    Site contact: Samir Macwan, MD · 760-531-4068 · samirmacwan@gmail.com

  • Colorado Springs Neurological Associates

    Colorado Springs, CO 80907

    Site contact: David Stevens, MD · 719-473-3272 · dstevens@csneuro.com

  • MedStar Washington Hospital Center

    Washington D.C., DC 20010

    Site contact: Yasir Al-Khalili, MD · 857-350-4834 · clinicaltrials@argenx.com

  • Homestead Associates in Research Inc

    Homestead, FL 33033

    Site contact: Christopher Jimenez, MD · 305-246-0873 · cjimenez@associatesinresearch.com

  • Visionary Investigators Network

    Miami, FL 33133

    Site contact: Andrew Lerman, MD · 786-655-8010 · alerman@fcneurology.net

  • University of South Florida

    Tampa, FL 33616

    Site contact: Kathleen Murray, MD · 813-974-9713 · kmurray11@usf.edu

  • Baptist Health Medical Group Neurology

    Nicholasville, KY 40356-6066

    Site contact: James Winkley · +1 857-350-4834 · clinicaltrials@argenx.com

  • Paradigm Health System

    Slidell, LA 70458

    Site contact: Patrick Glynn, MD · 985-882-4500 · trickpatglynn@yahoo.com

  • Erlanger Health System

    Columbia, MD 21044

    Site contact: Joshua Alpers, MD · 423-778-9001 · joshua.alpers@erlanger.org

  • University of Michigan Hospital

    Ann Arbor, MI 48109

    Site contact: Amro Stino, MD · 734-936-8586 · amstino@umich.edu

  • University of Cincinnati Health

    Cincinnati, OH 45267-2827

    Site contact: Hani Kushlaf, MD · +1 857-350-4834 · clinicaltrials@argenx.com

  • Perelman Center for Advanced Medicine

    Philadelphia, PA 19104-5127

    Site contact: Michael Baer, MD · 857-350-4834 · clinicaltrials@argenx.com

  • Jefferson Health Honickman Center

    Philadelphia, PA 19107

    Site contact: Goran Rakocevic, MD · 857-350-4834 · clinicaltrials@argenx.com

  • NeuroCarePlus

    Houston, TX 77094

    Site contact: Nicolas Nammour, MD · 281-579-6800 · nicolas.nammour@sclamanagement.com

  • National Neuromuscular Research Institute

    Irving, TX 75063

    Site contact: Yessar Hussain, MD · 512-920-0140 · yessar@austinneuromuscle.com

Study contacts (from the official record)

  • Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
All neurology studies in Alabama →
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg… (NCT06920004) | Bored Studies